Impax Laboratories
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Impax Laboratories sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Impax Laboratories: 19 sponsored US clinical trials, 1 recruiting.
Impax Laboratories sponsors 19 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 18 completed. 10 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson's Disease, with 4 trials.
Top-decile sponsor footprint
Impax Laboratories ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
19 total, page 1 of 1
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
NCT06765668
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
NCT06161220
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
NCT03877510
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
NCT03670953
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
NCT03275922
A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
NCT03007888
A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease
NCT02271503
Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)
NCT01521663
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
NCT01411137
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
NCT01130493
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
NCT01096186
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
NCT00974974
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
NCT00880620
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
NCT00914290
A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
NCT00869791
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
NCT00488839
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
NCT00279825
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
NCT00253084
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
NCT00239564
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
| Phase 3 | 9 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Impax Laboratories pipeline
1 recruiting of 19 indexed (5% open); 18 completed (95%).
Phase mix: 10 late (III/IV) vs 9 early (I/II) (balanced across stages).
Top condition: Parkinson's Disease (4 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Impax Laboratories: open-pipeline peers nationwide
Peers matched on 19 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Impax Laboratories sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 trials (± recruiting share)
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Defense and Veterans Center for Integrative Pain Management · 5% recruiting · 19 trials
- DePuy Orthopaedics · 5% recruiting · 38 trials
- Kent State University · 5% recruiting · 19 trials
- Omeros Corporation · 5% recruiting · 19 trials
Related
What to do with this Impax Laboratories page
19 registered trials is a research-attention snapshot, not an endorsement of Impax Laboratories or any single study.
- 1 of Impax Laboratories's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Parkinson's Disease is the condition Impax Laboratories studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Impax Laboratories pipeline card: 19 registered trials from official public datasets.Report a data error.